US
New research presented at ISPOR 2026 evaluates the health economic value of Colovac® — a novel colorectal anastomosis protection device designed as an alternative to creation of a diverting ostomy following colorectal resection.
The analysis examines the potential cost savings to U.S. payers of Colovac compared with diverting ostomy (standard of care). The results below suggest that use of Colovac may deliver meaningful cost savings driven by the reduced need for stomas, subsequent reversal procedures, and related stoma management and complication costs.
We invite you to download the full poster to explore the findings and methodology in greater detail.
Thank you to the coauthors: Anne M. Ryschon, Dr. John Marks, Jan B. Pietzsch, Dr. Simon Weber, and Abigail Garner.
#ISPORAnnual #SafeHeal #Colovac #ColorectalSurgery #HealthEconomics
In the US, Colovac is an investigational device limited by Federal law to investigational use. In the EU, Colovac is CE marked per EU MDR 2017-745.
About SafeHeal™
SafeHeal SAS, headquartered in Paris, France, and its wholly-owned U.S. subsidiary, SafeHeal Inc., is a clinical-stage medical device company which develops Colovac, a device invented by a French digestive surgeon, Dr. Charam Khosrovani, to obviate the need for a digestive ostomy in patients undergoing colorectal surgery. Colovac is a flexible bypass sheath intended to reduce the contact of fecal content at the anastomotic site following colorectal surgery. The device is placed endoluminally and is fully reversible. The device remains in place for 10 days, until the body’s natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. This enables patients to resume their normal life without the stigma and complications associated with an ostomy procedure. Colovac is an investigational device, not currently available for sale.